<?xml version="1.0" encoding="UTF-8" standalone="yes"?><dealRecordsOutput><serviceExecutionTime>256</serviceExecutionTime><Deal id="109470"><Title>Paladin to develop Stallergenes's Oralair therapies in Canada    </Title><CompanyPrincipal id="19274">Stallergenes SA</CompanyPrincipal><CompanyPartner id="27477">Paladin Labs Inc</CompanyPartner><Type>Drug - Development/Commercialization License</Type><Status>Active</Status><ValuesToPrincipal><ValuePaid accuracy="Unknown" max="0.0" min="0.0"/><ValueProjected accuracy="Payment Unspecified" max="0.0" min="0.0"/></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"/><ValueProjected accuracy="Unknown" max="0.0" min="0.0"/></ValuesToPartner><TerritoriesIncluded><Territory id="CA">Canada</Territory></TerritoriesIncluded><PaymentsProjected><PaymentsToPrincipal><Payment><Reference>756466</Reference><Type>Undisclosed</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>756466</Reference><Type>Undisclosed</Type><Value accuracy="Payment Unspecified"/></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="12">Allergy</Indication></Indications><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="12379">Therapeutic vaccine</Action><Action id="1570">Allergen</Action></ActionsSecondary><Technologies><Technology id="680">Buccal formulation systemic</Technology><Technology id="85">Protein recombinant</Technology></Technologies><DateStart>2007-01-09T00:00:00Z</DateStart><DateEventMostRecent>2007-01-09T00:00:00Z</DateEventMostRecent><Drugs><Drug id="55044"><DrugNameDisplay>grass-pollen allergen immunotherapy (sublingual tablet), Stallergenes/Paladin Labs/Greer Lab</DrugNameDisplay><PhaseHighestStart id="PR">Pre-registration</PhaseHighestStart><PhaseHighestNow id="L">Launched</PhaseHighestNow></Drug><Drug id="55054"><DrugNameDisplay>Actair</DrugNameDisplay><PhaseHighestStart id="C2">Phase 2 Clinical</PhaseHighestStart><PhaseHighestNow id="L">Launched</PhaseHighestNow></Drug><Drug id="55050"><DrugNameDisplay>recombinant Bet v 1 immunotherapy (birch pollen allergy), Stallergenes/Paladin</DrugNameDisplay><PhaseHighestStart id="C2">Phase 2 Clinical</PhaseHighestStart><PhaseHighestNow id="L">Launched</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In January 2007, &lt;ulink linkType="Company" linkID="19274"&gt;Stallergenes&lt;/ulink&gt;  granted &lt;ulink linkType="Company" linkID="27477"&gt;Paladin Labs&lt;/ulink&gt; Canadian development, promotion and distribution to its Oralair sublingual therapies for &lt;ulink linkType="Drug" linkID="55044"&gt;grass&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="55054"&gt;dust mite&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="55050"&gt;birch&lt;/ulink&gt; allergies [&lt;ulink linkType="Reference" linkID="756466"&gt;756466&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>2007-01-09T00:00:00Z</Date><Drugs><DrugLink id="55044" nameDisplay="grass-pollen allergen immunotherapy (sublingual tablet), Stallergenes/Paladin Labs/Greer Lab"/><DrugLink id="55050" nameDisplay="recombinant Bet v 1 immunotherapy (birch pollen allergy), Stallergenes/Paladin"/><DrugLink id="55054" nameDisplay="Actair"/></Drugs><Stage id="C3">Phase 3 Clinical</Stage><StageNotes>&lt;para&gt;Companies plan to submit the first application for Canadian regulatory approval of Oralair Grasses, in 2007.&lt;/para&gt;</StageNotes><Summary>&lt;para&gt;- In January 2007, &lt;ulink linkType="Company" linkID="19274"&gt;Stallergenes&lt;/ulink&gt;  granted &lt;ulink linkType="Company" linkID="27477"&gt;Paladin Labs&lt;/ulink&gt; Canadian development, promotion and distribution to its Oralair sublingual therapies for &lt;ulink linkType="Drug" linkID="55044"&gt;grass&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="55054"&gt;dust mite&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="55050"&gt;birch&lt;/ulink&gt; allergies.&lt;/para&gt;&lt;para&gt;- Oralair program contains three products Oralair Grasses, Oralair recombinant Bet V 1 (birch) and Oralair Mites, sublingual desensitization tablets for allergic rhinitis due to grass, birch and dust mites respectively.&lt;/para&gt;&lt;para&gt;- Companies plan to submit the first application for Canadian regulatory approval of Oralair Grasses, in 2007.&lt;/para&gt;&lt;para&gt;- Paladin would be  responsible for clinical trials, registration, marketing, sales and distribution of the products in that territory.&lt;/para&gt;&lt;para&gt;- Financial terms were not disclosed [&lt;ulink linkType="Reference" linkID="756466"&gt;756466&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event></TimeLine><CrossReferences><SourceEntity id="55044" type="Drug"><TargetEntity id="442424" type="siDrug">Oralair Grasses</TargetEntity></SourceEntity><SourceEntity id="55054" type="Drug"><TargetEntity id="442436" type="siDrug">S-524101</TargetEntity></SourceEntity><SourceEntity id="55050" type="Drug"><TargetEntity id="441532" type="siDrug">Recombinant Bet V1</TargetEntity></SourceEntity><SourceEntity id="19274" type="Company"><TargetEntity id="4295868053" type="organizationId">Stallergenes SA</TargetEntity></SourceEntity><SourceEntity id="27477" type="Company"><TargetEntity id="4295862339" type="organizationId">Paladin Labs Inc</TargetEntity></SourceEntity><SourceEntity id="12" type="ciIndication"><TargetEntity id="10001708" type="MEDDRA"/><TargetEntity id="1180" type="siCondition"/></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity></CrossReferences></Deal><Deal id="154365"><Title>University of Geneva to conduct preclinical studies of EspeRare's rimeporide against DMD </Title><CompanyPrincipal id="24222">University of Geneva</CompanyPrincipal><CompanyPartner id="1081667">EspeRare Foundation</CompanyPartner><Type>Drug - Early Research/Development</Type><Status>Active</Status><ValuesToPrincipal><ValuePaid accuracy="Unknown" max="0.0" min="0.0"/><ValueProjected accuracy="Payment Unspecified" max="0.0" min="0.0"/></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"/><ValueProjected accuracy="Unknown" max="0.0" min="0.0"/></ValuesToPartner><PaymentsProjected><PaymentsToPrincipal><Payment><Reference>1656533</Reference><Type>Undisclosed</Type><Value accuracy="Payment Unspecified"/></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="2020">Duchenne dystrophy</Indication></Indications><ActionsPrimary><Action id="2622">Sodium hydrogen exchanger modulator</Action></ActionsPrimary><ActionsSecondary><Action id="2659">Cardioprotectant</Action><Action id="1408">Muscle system agent</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology></Technologies><DateStart>2013-08-19T00:00:00Z</DateStart><DateEventMostRecent>2013-08-19T00:00:00Z</DateEventMostRecent><Drugs><Drug id="35482"><DrugNameDisplay>rimeporide</DrugNameDisplay><PhaseHighestStart id="C2">Phase 2 Clinical</PhaseHighestStart><PhaseHighestNow id="C1">Phase 1 Clinical</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In August 2013, &lt;ulink linkType="Company" linkID="1081667"&gt;EspeRare Foundation&lt;/ulink&gt; and &lt;ulink linkType="Company" linkID="24222"&gt;University of Geneva&lt;/ulink&gt; entered into a collaboration agreement for the development of &lt;ulink linkType="Drug" linkID="35482"&gt;rimeporide&lt;/ulink&gt; against Duchenne muscular dystrophy (DMD) [&lt;ulink linkType="Reference" linkID="1656533"&gt;1656533&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>2013-08-19T00:00:00Z</Date><Drugs><DrugLink id="35482" nameDisplay="rimeporide"/></Drugs><Stage id="C2">Phase 2 Clinical</Stage><StageNotes>&lt;para&gt;rimeporide is currently in preclinical phase for Duchenne muscular dystrophy&lt;/para&gt;</StageNotes><Summary>&lt;para&gt;- In August 2013, &lt;ulink linkType="Company" linkID="1081667"&gt;EspeRare Foundation&lt;/ulink&gt; and &lt;ulink linkType="Company" linkID="24222"&gt;University of Geneva&lt;/ulink&gt; entered into a collaboration agreement for the development of &lt;ulink linkType="Drug" linkID="35482"&gt;rimeporide&lt;/ulink&gt; against Duchenne muscular dystrophy (DMD).&lt;/para&gt;&lt;para&gt;- rimeporide is a Na+/H+ exchange-1 inhibitor  in preclinical phase for DMD. The drug had been previously developed by &lt;ulink linkType="Company" linkID="19862"&gt;Merck Serono&lt;/ulink&gt; for cardiac failure.&lt;/para&gt;&lt;para&gt;- University of Geneva would be responsible to  evaluate the dose and efficacy of rimeporide in a mice model and assess the efficacy in various cell lines.&lt;/para&gt;&lt;para&gt;- Preliminary data were expected by 2Q'2014.&lt;/para&gt;&lt;para&gt;- This preclinical work together with the already available data would support further development of rimeporide in patients with DMD.&lt;/para&gt;&lt;para&gt;- Financial terms were not disclosed [&lt;ulink linkType="Reference" linkID="1656533"&gt;1656533&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event></TimeLine><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="35482" type="Drug"><TargetEntity id="341789" type="siDrug">EMR-62204</TargetEntity></SourceEntity><SourceEntity id="24222" type="Company"><TargetEntity id="4298324203" type="organizationId">L Universite De Geneve</TargetEntity></SourceEntity><SourceEntity id="1081667" type="Company"><TargetEntity id="5039581669" type="organizationId">EspeRare Foundation</TargetEntity></SourceEntity><SourceEntity id="2020" type="ciIndication"><TargetEntity id="10013801" type="MEDDRA"/><TargetEntity id="D020388" type="MeSH"/><TargetEntity id="98896" type="ORPHANET"/><TargetEntity id="-2123687174" type="omicsDisease"/><TargetEntity id="143" type="siCondition"/></SourceEntity></CrossReferences></Deal><Deal id="155560"><Title>Navidea to receive grant from NHLBI to evaluate Manocept for detection of cardiovascular diseases </Title><CompanyPrincipal id="1003240">National Heart Lung and Blood Institute</CompanyPrincipal><CompanyPartner id="18471">Navidea Biopharmaceuticals Inc</CompanyPartner><Type>Drug - Funding</Type><Status>Active</Status><ValuesToPrincipal><ValuePaid accuracy="=" max="0.32" min="0.32"/><ValueProjected accuracy="=" max="0.64" min="0.64"/></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"/><ValueProjected accuracy="Unknown" max="0.0" min="0.0"/></ValuesToPartner><PaymentsProjected><PaymentsToPrincipal><Payment><Reference>1681296</Reference><Type>R&amp;D Funding</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="0.32" usdExchangeRate="1.0" usdExchangeRatePeriod="2015 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1681296</Reference><Type>R&amp;D Funding</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="0.32" usdExchangeRate="1.0" usdExchangeRatePeriod="2015 Q2">0.0</ReportedAmountMil></Value></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="57">Cardiovascular disease</Indication></Indications><ActionsPrimary><Action id="53095">Macrophage mannose receptor 1 modulator</Action></ActionsPrimary><ActionsSecondary><Action id="449">Antiarrhythmic agent</Action><Action id="5720">Radiodiagnostic</Action><Action id="7213">Gastrointestinal diagnostic agent</Action><Action id="7210">Cardiovascular diagnostic agent</Action><Action id="7220">Neoplasm diagnostic agent</Action><Action id="4156">Ultrasound contrast agent</Action><Action id="7212">Endocrine diagnostic agent</Action><Action id="7217">Autoimmune diagnostic agent</Action></ActionsSecondary><Technologies><Technology id="147">Diagnostic method</Technology><Technology id="726">Fluorescence</Technology><Technology id="731">Imaging</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="724">Radiolabeling</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="603">Systemic formulation unspecified</Technology></Technologies><DateStart>2015-07-28T00:00:00Z</DateStart><DateEventMostRecent>2015-07-28T00:00:00Z</DateEventMostRecent><Drugs><Drug id="34061"><DrugNameDisplay>technetium Tc 99m tilmanocept</DrugNameDisplay><PhaseHighestStart id="L">Launched</PhaseHighestStart><PhaseHighestNow id="L">Launched</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In July 2015, &lt;ulink linkType="Company" linkID="18471"&gt;Navidea Biopharmaceuticals&lt;/ulink&gt; was awarded a phase I SBIR grant from the &lt;ulink linkType="Company" linkID="1003240"&gt;National Heart Lung and Blood Institute&lt;/ulink&gt;  (NHLBI) to evaluate &lt;ulink linkType="Drug" linkID="34061"&gt;Manocept&lt;/ulink&gt; for detection of cardiovascular diseases [&lt;ulink linkType="Reference" linkID="1681296"&gt;1681296&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>2015-07-28T00:00:00Z</Date><Drugs><DrugLink id="34061" nameDisplay="technetium Tc 99m tilmanocept"/></Drugs><PaymentsToPrincipal><Payment><Reference id="1681296">1681296</Reference><Type>R&amp;D Funding</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2015 Q2" exchangeRateUS="1">0.32</USDAmountMil></Value></Payment></PaymentsToPrincipal><Stage id="L">Launched</Stage><StageNotes>&lt;para&gt;Lymphoseek was approved by the U.S. FDA for use in solid tumor cancers&lt;/para&gt;</StageNotes><Summary>&lt;para&gt;- In July 2015, &lt;ulink linkType="Company" linkID="18471"&gt;Navidea Biopharmaceuticals&lt;/ulink&gt; was awarded a $0.321million phase I SBIR grant from the &lt;ulink linkType="Company" linkID="1003240"&gt;National Heart Lung and Blood Institute&lt;/ulink&gt;  (NHLBI) to evaluate &lt;ulink linkType="Drug" linkID="34061"&gt;Manocept&lt;/ulink&gt; for detection of cardiovascular diseases.&lt;/para&gt;&lt;para&gt;- The study would be conducted in collaboration with the &lt;ulink linkType="Company" linkID="21569"&gt;Massachusetts General Hospital&lt;/ulink&gt; (MGH) and &lt;ulink linkType="Company" linkID="24839"&gt;Harvard Medical School&lt;/ulink&gt;.&lt;/para&gt;&lt;para&gt;- Lymphoseek is an FDA-approved receptor-targeted lymphatic mapping agent. It is a receptor-targeted, small-molecule radiopharmaceutical used in the evaluation of lymphatic basins that may have cancer involvement in patients.&lt;/para&gt;&lt;para&gt;- Lymphoseek was approved by the U.S. FDA for use in solid tumor cancers where lymphatic mapping is a component of surgical management and for guiding sentinel lymph node biopsy in patients with clinically node negative breast cancer, melanoma or squamous cell carcinoma of the oral cavity.&lt;/para&gt;&lt;para&gt;- The study would examine the ability of Tc 99m-tilmanocept (Lymphoseek), a Manocept platform product, to localize in high-risk atherosclerotic plaques.&lt;/para&gt;&lt;para&gt;- Lymphoseek has also received European approval in imaging and intraoperative detection of sentinel lymph nodes in patients with melanoma, breast cancer or localized squamous cell carcinoma of the oral cavity.&lt;/para&gt;&lt;para&gt;- The grant would help in the clinical investigation of up to 18 individuals with and without aortic and high risk coronary atherosclerotic plaques and with and without HIV infection to determine the feasibility of 99mTc-tilmanocept to image high risk plaque by SPECT/CT  [&lt;ulink linkType="Reference" linkID="1681296"&gt;1681296&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event></TimeLine><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="34061" type="Drug"><TargetEntity id="381053" type="siDrug">Technetium Tc 99m tilmanocept</TargetEntity></SourceEntity><SourceEntity id="1003240" type="Company"><TargetEntity id="5035524536" type="organizationId">National Heart Lung and Blood Institute</TargetEntity></SourceEntity><SourceEntity id="18471" type="Company"><TargetEntity id="4295907361" type="organizationId">Navidea Biopharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="57" type="ciIndication"><TargetEntity id="10007649" type="MEDDRA"/><TargetEntity id="D002318" type="MeSH"/><TargetEntity id="-1500764314" type="omicsDisease"/><TargetEntity id="182" type="siCondition"/></SourceEntity><SourceEntity id="53095" type="Action"><TargetEntity id="6760" type="Mechanism">Macrophage Mannose Receptor (MRC1) Ligands</TargetEntity></SourceEntity></CrossReferences></Deal><Deal id="162554"><Title>MJFF to award Cognition Therapeutics funding to study inhibitors of alpha-synuclein oligomers against Parkinson's disease               </Title><CompanyPrincipal id="1043847">Cognition Therapeutics Inc</CompanyPrincipal><CompanyPartner id="1038884">The Michael J. Fox Foundation</CompanyPartner><Type>Drug - Funding</Type><Status>Active</Status><ValuesToPrincipal><ValuePaid accuracy="Payment Unspecified" max="0.0" min="0.0"/><ValueProjected accuracy="Payment Unspecified" max="0.0" min="0.0"/></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"/><ValueProjected accuracy="Unknown" max="0.0" min="0.0"/></ValuesToPartner><PaymentsProjected><PaymentsToPrincipal><Payment><Reference>1802882</Reference><Type>R&amp;D Funding</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1802882</Reference><Type>R&amp;D Funding</Type><Value accuracy="Payment Unspecified"/></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="255">Parkinsons disease</Indication></Indications><ActionsPrimary><Action id="11109">Synuclein alpha modulator</Action></ActionsPrimary><ActionsSecondary><Action id="2947">Antiparkinsonian</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><DateStart>2016-09-29T00:00:00Z</DateStart><DateEventMostRecent>2016-09-29T00:00:00Z</DateEventMostRecent><Drugs><Drug id="101961"><DrugNameDisplay>alpha synuclein modulators (Parkinsons disease), Cognition Therapeutics</DrugNameDisplay><PhaseHighestStart id="PC">Preclinical</PhaseHighestStart><PhaseHighestNow id="DR">Discovery</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In  September 2016, &lt;ulink linkType="Company" linkID="1043847"&gt;Cognition Therapeutics&lt;/ulink&gt; (CogRx) received a grant from &lt;ulink linkType="Company" linkID="1038884"&gt;Michael J. Fox Foundation&lt;/ulink&gt;  (MJFF) to study &lt;ulink linkType="Drug" linkID="101961"&gt;inhibitors of alpha-synuclein oligomers&lt;/ulink&gt; for the treatment of Parkinson's disease (PD) [&lt;ulink linkType="Reference" linkID="1802882"&gt;1802882&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>2016-09-29T00:00:00Z</Date><Drugs><DrugLink id="101961" nameDisplay="alpha synuclein modulators (Parkinsons disease), Cognition Therapeutics"/></Drugs><PaymentsToPrincipal><Payment><Reference id="1802882">1802882</Reference><Type>R&amp;D Funding</Type><Value><Accuracy sortorder="2">Payment Unspecified</Accuracy></Value></Payment></PaymentsToPrincipal><Stage id="PC">Preclinical</Stage><StageNotes>&lt;para&gt;The drug alpha synuclein modulators was in preclinical stage.&lt;/para&gt;</StageNotes><Summary>&lt;para&gt;- In  September 2016, &lt;ulink linkType="Company" linkID="1043847"&gt;Cognition Therapeutics&lt;/ulink&gt; (CogRx) received an undisclosed grant from &lt;ulink linkType="Company" linkID="1038884"&gt;Michael J. Fox Foundation&lt;/ulink&gt;  (MJFF) to study &lt;ulink linkType="Drug" linkID="101961"&gt;inhibitors of alpha-synuclein oligomers&lt;/ulink&gt; for the treatment of Parkinson's disease (PD).&lt;/para&gt;&lt;para&gt;- The alpha synuclein modulators, for the  treatment of Parkinson's disease, was currently  in preclinical stage.&lt;/para&gt;&lt;para&gt;- The grant provides rigorous peer-reviewed validation of  approach  to PD, and would enable  to discover drug candidates capable of stopping the toxic protein forms that cause the disease.&lt;/para&gt;&lt;para&gt;- CogRx would  be able to optimize an initial drug candidate to improve effectiveness at stopping the toxicity and will then test these in validated animal models, If the research was successful    [&lt;ulink linkType="Reference" linkID="1802882"&gt;1802882&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event></TimeLine><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="1038884" type="Company"><TargetEntity id="5035525395" type="organizationId">Michael J Fox Foundation for Parkinson's Research</TargetEntity></SourceEntity><SourceEntity id="1043847" type="Company"><TargetEntity id="4297947191" type="organizationId">Cognition Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="255" type="ciIndication"><TargetEntity id="G20" type="ICD10"/><TargetEntity id="10061536" type="MEDDRA"/><TargetEntity id="D010300" type="MeSH"/><TargetEntity id="-342157116" type="omicsDisease"/><TargetEntity id="127" type="siCondition"/></SourceEntity><SourceEntity id="11109" type="Action"><TargetEntity id="5414" type="Mechanism">Drugs Targeting alpha-Synuclein (ASYN; NACP) </TargetEntity></SourceEntity></CrossReferences></Deal><Deal id="256733"><Title>Catalent to manufacture AAV vector for IVERIC Bio's IC-100 and IC-200</Title><CompanyPrincipal id="1034675">Catalent Inc</CompanyPrincipal><CompanyPartner id="1033865">IVERIC Bio Inc</CompanyPartner><Type>Drug - Manufacturing/Supply</Type><Status>Active</Status><ValuesToPrincipal><ValuePaid accuracy="Unknown" max="0.0" min="0.0"/><ValueProjected accuracy="Payment Unspecified" max="0.0" min="0.0"/></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"/><ValueProjected accuracy="Unknown" max="0.0" min="0.0"/></ValuesToPartner><PaymentsProjected><PaymentsToPrincipal><Payment><Reference>2165123</Reference><Type>Undisclosed</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>2165123</Reference><Type>Undisclosed</Type><Value accuracy="Payment Unspecified"/></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="288">Retinopathy</Indication></Indications><ActionsPrimary><Action id="67243">RHO gene stimulator</Action><Action id="26196">BEST gene stimulator</Action></ActionsPrimary><ActionsSecondary><Action id="4781">Adeno-associated virus based gene therapy</Action></ActionsSecondary><Technologies><Technology id="62">Virus recombinant</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="620">Ophthalmic formulation</Technology></Technologies><DateStart>2019-06-17T00:00:00Z</DateStart><DateEventMostRecent>2019-06-17T00:00:00Z</DateEventMostRecent><Drugs><Drug id="85152"><DrugNameDisplay>IC-200</DrugNameDisplay><PhaseHighestStart id="PC">Preclinical</PhaseHighestStart><PhaseHighestNow id="DR">Discovery</PhaseHighestNow></Drug><Drug id="116376"><DrugNameDisplay>IC-100, IVERIC Bio</DrugNameDisplay><PhaseHighestStart id="PC">Preclinical</PhaseHighestStart><PhaseHighestNow id="DR">Discovery</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In June 2019, &lt;ulink linkType="Company" linkID="1033865"&gt;IVERIC bio&lt;/ulink&gt; signed an agreement with &lt;ulink linkType="Company" linkID="1034675"&gt;Catalent Biologics&lt;/ulink&gt; for the production and manufacturing of GMP-grade adeno-associated virus (AAV) vector for &lt;ulink linkType="Drug" linkID="116376"&gt;IC-100&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="85152"&gt;IC-200&lt;/ulink&gt; for retinal diseases [&lt;ulink linkType="Reference" linkID="2165123"&gt;2165123&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>2019-06-17T00:00:00Z</Date><Drugs><DrugLink id="116376" nameDisplay="IC-100, IVERIC Bio"/><DrugLink id="85152" nameDisplay="IC-200"/></Drugs><Stage id="PC">Preclinical</Stage><StageNotes>&lt;para&gt;IC-200 was in preclinical stage against retinal diseases.&lt;/para&gt;</StageNotes><Summary>&lt;para&gt;-  In June 2019, &lt;ulink linkType="Company" linkID="1033865"&gt;IVERIC bio&lt;/ulink&gt; signed an agreement with &lt;ulink linkType="Company" linkID="1034675"&gt;Catalent Biologics&lt;/ulink&gt; for the production and manufacturing of GMP-grade adeno-associated virus (AAV) vector for &lt;ulink linkType="Drug" linkID="116376"&gt;IC-100&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="85152"&gt;IC-200&lt;/ulink&gt; for retinal diseases.&lt;/para&gt;&lt;para&gt;- IC-200 is an adeno-associated viral vector 2 (AAV2)-delivered gene therapy for Best-1 gene for the treatment of retinopathies.&lt;/para&gt;&lt;para&gt;- IC-100 is an adeno-associated viral vector 5 (AAV5)-delivered gene therapy for rhodopsin (RHO) gene for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa.&lt;/para&gt;&lt;para&gt;- Financial terms were undisclosed [&lt;ulink linkType="Reference" linkID="2165123"&gt;2165123&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event></TimeLine><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="1034675" type="Company"><TargetEntity id="4295911386" type="organizationId">Catalent Pharma Solutions Inc</TargetEntity></SourceEntity><SourceEntity id="1033865" type="Company"><TargetEntity id="4297721792" type="organizationId">Iveric Bio Inc</TargetEntity></SourceEntity><SourceEntity id="288" type="ciIndication"><TargetEntity id="10038923" type="MEDDRA"/><TargetEntity id="D012164" type="MeSH"/><TargetEntity id="-422908255" type="omicsDisease"/><TargetEntity id="1944" type="siCondition"/><TargetEntity id="794" type="siCondition"/></SourceEntity></CrossReferences></Deal></dealRecordsOutput>